Sanofi expands Owkin partnership for purpose-built AI agents
Sanofi has signed a multi-year collaboration agreement with Owkin, the Franco-American agentic AI company, to co-develop bespoke AI agents deployed through K Pro, Owkin's AI Scientist platform — extending a partnership that dates to 2021 and now covers Sanofi's full pharmaceutical value chain. The arrangement includes a five-year license for K Pro and positions Owkin as the end-to-end builder of purpose-built agents integrated into Sanofi's existing agentic AI workflows. Financial terms were not disclosed.
The collaboration builds on a prior EUR 90 million (approximately USD 104 million) strategic partnership initiated in 2021, which focused on target identification across four oncology programs and was later expanded to include drug positioning for Sanofi's immunology pipeline. The current agreement represents a structural shift: where earlier work was program-specific, the K Pro license is platform-wide, designed to operate across Sanofi's entire R&D continuum from early discovery through clinical development.
K Pro is described by Owkin as an agentic AI platform built on multimodal biological data — including genomics, histopathology imaging, and clinical outcomes — combined with what the company calls biological reasoning models. Central to the architecture is Owkin Zero, a 32-billion parameter model trained on approximately 10 million curated biomedical question-and-answer pairs, designed to execute mechanistic scientific reasoning rather than general text retrieval. Proprietary histology foundation models, including H0 and iBOT, trained on more than 200,000 pathologist annotations, provide a spatial tissue-level reasoning layer. Under the Sanofi arrangement, Owkin will develop AI agents that autonomously perform complex tasks — competitive intelligence, landscape forecasting, target evaluation, and clinical decision support — deployed within Sanofi's internal governance and security frameworks.
The scope is deliberately enterprise-wide rather than indication-specific. Owkin previously entered a three-year license agreement with AstraZeneca for K Pro in May 2026, where initial capabilities focused on competitive intelligence for specific targets and assets. The Sanofi arrangement appears broader, covering co-development of novel agents across multiple workflow categories rather than a single defined use case.
Industry and transaction context
The deal reflects a pattern among large pharma companies of sourcing AI platform capabilities through time-limited licensing arrangements with a vendor-led build component, rather than through acquisitions or equity stakes. The AstraZeneca K Pro deal, announced three weeks prior, followed the same structural logic — a defined term, Owkin-led agent development, and deployment within the pharma's own IT environment. Two major pharma companies licensing the same platform within weeks of each other is notable for a privately held AI vendor and suggests Owkin is actively converting its prior pharma relationships into recurring platform revenue.
Sanofi's AI partnering behavior has been consistent across modalities. In January 2026, Sanofi extended its collaboration with CytoReason for AI-powered computational disease modeling in a deal valued at up to USD 16 million — its third expansion of that relationship. The CytoReason deal is structured around proprietary disease models and evidence graphs rather than agentic workflow execution, illustrating that Sanofi is layering multiple AI vendors with distinct technical approaches rather than consolidating on a single platform. The K Pro collaboration occupies a different functional layer: autonomous agent execution across the R&D value chain rather than disease-specific predictive modeling.
Sanofi's broader AI vendor portfolio also includes a worldwide exclusive license with Earendil Labs for AI-discovered bispecific antibodies in autoimmune disease, announced in April 2025 with USD 125 million upfront and up to USD 1.72 billion in milestones. That deal follows traditional biopharma licensing economics tied to specific molecules. The K Pro arrangement sits in a structurally different category — platform access rather than asset acquisition — and the two approaches are complementary rather than substitutive within Sanofi's AI sourcing strategy.
This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/
Spot something wrong? Report an issue with this article
Summary
Sanofi has signed a multi-year collaboration agreement with Owkin, the Franco-American agentic AI company, to co-develop bespoke AI agents deployed through...